Latest Breaking News On - Patient reported outcomes - Page 4 : comparemela.com

Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS

Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.

Amy dezernEvolving treatment landscapeMyelodysplastic syndromesClaims dataPatient reported outcomesMds treatmentMyelodysplastic syndromes treatmentMash 2023Real world outcomesCommands trialCommands studyHealthcare claimsHealthcare claims database

Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrank siebenhaarAndrew robbinsHead university outpatient clinicData monitoring committeeCogent biosciences incBezuclastinib clinical developmentInstitute of allergologyCogent biosciencesAllergy asthmaImmunology annual meetingChief executivePatient reported outcomesMastocytosis symptom severity daily diaryMast cell quality of lifeClinical development based

Cogent Biosciences Announces Positive Part 1b Data from

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based.

United statesAndrew robbinsFrank siebenhaarChristi waarichData monitoring committeeHead university outpatient clinicCogent biosciences incBezuclastinib clinical developmentCogent research teamInstitute of allergologyTotal symptom scoreAllergy asthmaImmunology annual meetingChief executivePatient reported outcomesMastocytosis symptom severity daily diary

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew robbinsChristi waarichFrank siebenhaarCogent research teamData monitoring committeeCogent biosciences incBezuclastinib clinical developmentInstitute of allergologyHead university outpatient clinicBiosciences announces positive partEvaluating bezuclastinibNonadvanced systemicTotal symptom scoreAllergy asthmaImmunology annual meeting

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: 51% week 12 mean change in Total Symptom.

United statesChristi waarichFrank siebenhaarAndrew robbinsCogent biosciences incHead university outpatient clinicData monitoring committeeBezuclastinib clinical developmentGlobenewswire incCogent research teamInstitute of allergologyTotal symptom scoreAllergy asthmaImmunology annual meetingUniversity outpatient clinicChief executive